Table 2.
Comparison of clinical data of the two groups (( ± s)/n(%)).
| Index | Low-quality group (n = 52) | High-quality group (n = 52) | Z/t/χ 2 | P |
|---|---|---|---|---|
| Age (year) | 68.71 ± 5.66 | 59.57 ± 6.67 | 5.892 | <0.001 |
| Sex (male/female) | 34/18 | 26/26 | 2.521 | 0.112 |
| BMI (kg/m2) | 23.12 ± 2.14 | 24.01 ± 2.49 | −1.955 | 0.053 |
|
| ||||
| Complication (n(%)) | ||||
| Hypertension | 11 (21.15) | 9 (17.31) | 0.248 | 0.619 |
| Diabetes | 8 (15.38) | 6 (11.54) | 0.330 | 0.566 |
| Hyperlipidemia | 6 (11.54) | 2 (3.85) | 2.167 | 0.141 |
|
| ||||
| Clinical stage (n(%)) | 1.493 | 0.222 | ||
| I | 16 (30.77) | 22 (42.31) | ||
| II | 36 (69.23) | 30 (57.69) | ||
| Living alone (n(%)) | 16 (30.77) | 4 (7.69) | 8.914 | 0.003 |
| Metastasis (n(%)) | 19 (36.54) | (40.38) | 0.163 | 0.687 |
|
| ||||
| Surgical methods (n(%)) | 0.768 | 0.443 | ||
| Lobectomy | 15 (28.85) | 11 (21.15) | 0.242 | 0.623 |
| Segmental resection | 16 (30.77) | 17 (32.69) | 1.083 | 0.298 |
| Wedge resection | 21 (40.38) | 24 (46.15) | 3.581 | 0.058 |
|
| ||||
| Adjuvant therapy (n(%)) | 0.977 | 0.329 | ||
| Radiotherapy | 11 (21.15) | 14 (26.92) | ||
| Chemotherapy | 34 (65.38) | 35 (67.31) | ||
| Others | 7 (13.46) | 3 (5.77) | ||
| S-AI (point) | 54.10 ± 7.96 | 42.70 ± 7.66 | 7.442 | <0.001 |
| FoP-Q-SF (point) | 37.70 ± 6.10 | 29.86 ± 7.14 | 6.019 | <0.001 |
| Serum CEA (ng/mL) | 44.87 ± 8.43 | 46.26 ± 9.75 | 0.778 | 0.439 |
| Serum creatinine (μmol/L) | 59.89 ± 11.51 | 61.47 ± 10.32 | 0.737 | 0.463 |
| Alanine aminotransferase (U/L) | 30.11 ± 5.89 | 31.76 ± 5.25 | 1.508 | 0.135 |
| Albumin (g/L) | 57.11 ± 10.04 | 71.79 ± 12.24 | 6.688 | <0.001 |
| PaO2 (mmHg) | 92.57 ± 10.45 | 96.31 ± 11.96 | 1.698 | 0.093 |
| PaCO2 (mmHg) | 40.96 ± 3.85 | 39.93 ± 3.54 | 1.420 | 0.159 |